US FDA panel embraces GSK/HGS anthrax drug raxibacumab
This article was originally published in Scrip
Executive Summary
Human Genome Science, a subsidiary of GlaxoSmithKline, on 2 November had little difficulty convincing a US FDA panel of outside advisers to back approval of the company's experimental inhalational anthrax drug, raxibacumab.